Oncology
Liquid biopsy and the future of tumour-agnostic treatments
Liquid biopsy-based tools are positioned as a critical enabler of tumour-agnostic therapeutic development.
News
UK will be first market for Sanofi's subcutaneous Sarclisa
Sanofi's on-body injector version of multiple myeloma therapy Sarclisa has been cleared in the UK, which will be the first market for the product.
News
Jazz orchestrates a $4bn cancer alliance with AbCellera
Jazz Pharma has made a big move into T-cell engagers (TCEs) for solid tumours, via an alliance with Canadian biotech AbCellera.
Oncology
Radiopharma in 2026 & beyond, with ITM's Dr Andrew Cavey
Dr Andrew Cavey, CEO of ITM, discusses current and future radiopharmaceutical trends.
News
Poolbeg expects first data for CRS drug in the summer
A trial to see if Poolbeg's POLB-001 can prevent cytokine release syndrome in multiple myeloma treated with immunotherapy Tecvayli will start soon.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
